Pembrolizumab或奥拉帕利对 BRCA 突变和 MSI-H 的患者的最佳一线治疗仍存在争议,因此,需要足够的成像方式或生物标志物,进一步积累病例和临床试验来确定这种选择的有效性。 参考文献>> [1] Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, et al. BRCA mutations in prostate cancer: ...
MSI-H or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine,...
First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case reportMuir-Torre Syndromelynch syndromeprostate cancerimmunotherapymicrosatellite instability (MSI)...
dMMR = mismatch repair deficient; DNA = deoxyribonucleic acid; GEJ = gastroesophageal junction; HNSCC = head and neck squamous cell carcinoma; MLH = MutL homologue; MMR = mismatch repair; MSI = microsatellite instability; MSI-H = microsatellite instability-high; NOS = not otherwise specifi...
(R2) disease, or metastatic biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer that is microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR), or tumor mutational burden high (TMB-H) (greater than or equal to 10 mutations/...
Prior to that, in July 2021, the FDA granted a regular approval to pembrolizumab and lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression after...
Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by ...
Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, tha...
Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatc...
biomarkers are most commonly found in colorectal, endometrial and gastrointestinal cancers, but also less commonly appear in cancers arising in the breast, prostate, bladder, thyroid gland and other places. Approximately 5 percent of patients with metastatic colorectal cancer have MSI-H ...